SCINTIX Therapy Leverages Breakthrough Device Status to Garner Accretive New Technology Reimbursement

In a landscape of declining Medicare reimbursements for conventional radiotherapy over the past decade, SCINTIX® therapy stands alone as a new modality in radiation therapy that bucks the trend. In January 2024, SCINTIX therapy was granted accretive reimbursement compared to other radiotherapy modalities. The Centers for Medicare and Medicaid Services (CMS) established a national payment […] The post SCINTIX Therapy Leverages Breakthrough Device Status to Garner Accretive New Technology Reimbursement appeared first on RefleXion .